Vaxil Bio Ltd.

Equities

VXL

CA92243L1076

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 08:35:56 22/05/2024 pm IST			5-day change	1st Jan Change
0.01 ^CAD	-.--%		-.--%	-60.00%

30/05	Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
27/05	Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. in a reverse merger transaction.	CI

Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 31, 2024 at 02:59 am IST

Vaxil Bio Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was CAD 0.058 million compared to CAD 0.125 million a year ago.

Latest news about Vaxil Bio Ltd.

Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	31/05	CI
Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. in a reverse merger transaction.	27/05	CI
Vaxil Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/04	CI
Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. in a reverse merger transaction.	04/03	CI
Vaxil Bio Entered Into Letter Of Intent With Copper Bullet Mines In Respect Of A Proposed Reverse Takeover	11/01	MT
Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. for CAD 15.8 million in a reverse merger transaction.	10/01	CI
Vaxil Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Vaxil Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/23/28	CI
Vaxil Bio Ltd. Announces CFO Changes	03/23/03	CI
Vaxil Bio Ltd. Announces CEO Changes	03/23/03	CI
Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/23/30	CI
Vaxil Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Vaxil Bio Ltd. Auditor Raises 'Going Concern' Doubt	27/23/27	CI
Vaxil Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
Vaxil Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/22/26	CI
Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Vaxil Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30	CI
Vaxil Bio Ltd. Auditor Raises 'Going Concern' Doubt	29/22/29	CI
Vaxil Bio Provides Update on Research Activities	07/22/07	MT
Vaxil Bio Provides Final Results on Research With Ben-Gurion University	04/22/04	MT
Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOX	04/22/04	CI
Vaxil Bio Ltd. Announces Resignation of David Goren as Director	14/21/14	CI
Vaxil Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	26/21/26	CI
Vaxil Bio Will Not Move Ahead with the Acquisition of Short Wave Pharma Following Due Diligence	11/21/11	MT
Vaxil Bio Ltd. cancelled the acquisition of Short Wave Pharma Inc.	11/21/11	CI

Chart Vaxil Bio Ltd.

Duration

Period

More charts

Company Profile

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Companyâs most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VAXIL BIO LTD.	-60.00%	1M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+25.27%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.59%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs